We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
AJOVY (Teva Pharma Australia Pty Ltd)
Product name
AJOVY
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
202 working days (255)
Active ingredients
fremanezumab
Registration type
NCE/NBE
Indication
AJOVY (solution for injection) is indicated for the preventive treatment of migraine in adults.